{
  "data": [
    {
      "title": "Cancer Drug Fund Criteria",
      "paragraphs": [
        {
          "context": "Alectinib monotherapy for adjuvant treatment in adults after complete tumour resection in patients with stage IB-IIIA non-small cell lung cancer whose tumours have an ALK gene rearrangement where the following criteria have been met...",
          "qas": [
            {
              "id": "1",
              "question": "Can Alectinib be used for non-small cell lung cancer?",
              "answers": [
                {
                  "text": "Alectinib is indicated for adjuvant treatment in adults after complete tumour resection in patients with stage IB-IIIA non-small cell lung cancer with ALK gene rearrangement.",
                  "answer_start": 0
                }
              ],
              "is_impossible": false
            }
          ]
        },
        {
          "context": "Atezolizumab monotherapy for adjuvant treatment after complete tumour resection in adult patients with PD-L1 expression on ≥50% of tumour cells...",
          "qas": [
            {
              "id": "2",
              "question": "What are the criteria for using Atezolizumab?",
              "answers": [
                {
                  "text": "Atezolizumab is for patients with PD-L1 expression on ≥50% of tumour cells and who have completed adjuvant platinum-based chemotherapy.",
                  "answer_start": 37
                }
              ],
              "is_impossible": false
            }
          ]
        },
        {
          "context": "Avapritinib is indicated for the treatment of aggressive systemic mastocytosis or mast cell leukaemia...",
          "qas": [
            {
              "id": "3",
              "question": "For which conditions can Avapritinib be used?",
              "answers": [
                {
                  "text": "Aggressive systemic mastocytosis or mast cell leukaemia.",
                  "answer_start": 34
                }
              ],
              "is_impossible": false
            }
          ]
        },
        {
          "context": "Belzutifan is for adult patients with von Hippel-Lindau (VHL) disease requiring systemic therapy for VHL associated renal cell carcinoma...",
          "qas": [
            {
              "id": "4",
              "question": "Can Belzutifan be used for renal cell carcinoma?",
              "answers": [
                {
                  "text": "Belzutifan is used for VHL associated renal cell carcinoma when localised procedures are unsuitable.",
                  "answer_start": 34
                }
              ],
              "is_impossible": false
            }
          ]
        },
        {
          "context": "Axicabtagene ciloleucel is used for treating relapsed/refractory diffuse large B-cell lymphoma...",
          "qas": [
            {
              "id": "5",
              "question": "Is Axicabtagene ciloleucel indicated for lymphoma?",
              "answers": [
                {
                  "text": "Axicabtagene ciloleucel is used for relapsed/refractory diffuse large B-cell lymphoma.",
                  "answer_start": 23
                }
              ],
              "is_impossible": false
            }
          ]
        }
      ]
    }
  ]
}
